197 related articles for article (PubMed ID: 34718518)
1. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
[No Abstract] [Full Text] [Related]
2. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
[No Abstract] [Full Text] [Related]
3. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
Patoulias D; Papadopoulos C; Doumas M
J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
[No Abstract] [Full Text] [Related]
6. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta
Joshi SS; Singh T; Singh J; Newby DE
Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972
[No Abstract] [Full Text] [Related]
7. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
Chilton RJ
Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
[No Abstract] [Full Text] [Related]
8. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
Crea F
Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
[No Abstract] [Full Text] [Related]
9. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
Liang B; Gu N
Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
[No Abstract] [Full Text] [Related]
11. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.
Cure E; Cumhur Cure M
Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553
[No Abstract] [Full Text] [Related]
12. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
Khan MS; Butler J; Greene SJ
Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
[No Abstract] [Full Text] [Related]
13. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
14. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.
Docherty KF; McMurray JJV
Eur J Heart Fail; 2021 Jan; 23(1):27-30. PubMed ID: 33283384
[No Abstract] [Full Text] [Related]
15. Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors.
Carbone S; Dixon DL; Abbate A
JACC Heart Fail; 2018 Jan; 6(1):85. PubMed ID: 29284585
[No Abstract] [Full Text] [Related]
16. Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Joshi
Yalta K; Ozkan U; Yalta T
Heart; 2021 Dec; 107(23):1922. PubMed ID: 34656974
[No Abstract] [Full Text] [Related]
17. [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes].
Gronda E; Napoli C; Iacoviello M; Urbinati S; Caldarola P; Mannucci E; Colivicchi F; Gabrielli D
G Ital Cardiol (Rome); 2021 Aug; 22(8):675-687. PubMed ID: 34310573
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
19. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
Honigberg MC; Vardeny O; Vaduganathan M
Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
[No Abstract] [Full Text] [Related]
20. Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming.
Cimino G; Pancaldi E; Tomasoni D; Lombardi CM; Metra M; Adamo M
J Cardiovasc Med (Hagerstown); 2022 Dec; 23(12):761-769. PubMed ID: 36349941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
